IL315648A - Combination therapy of SOS1 inhibitor and MEK inhibitor - Google Patents
Combination therapy of SOS1 inhibitor and MEK inhibitorInfo
- Publication number
- IL315648A IL315648A IL315648A IL31564824A IL315648A IL 315648 A IL315648 A IL 315648A IL 315648 A IL315648 A IL 315648A IL 31564824 A IL31564824 A IL 31564824A IL 315648 A IL315648 A IL 315648A
- Authority
- IL
- Israel
- Prior art keywords
- combination
- inhibitor
- use according
- mek inhibitor
- sos1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329104P | 2022-04-08 | 2022-04-08 | |
| PCT/US2023/017254 WO2023196218A2 (en) | 2022-04-08 | 2023-04-03 | Combination therapies comprising a sos1 inhibitor and a mek inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315648A true IL315648A (en) | 2024-11-01 |
Family
ID=88243402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315648A IL315648A (en) | 2022-04-08 | 2023-04-03 | Combination therapy of SOS1 inhibitor and MEK inhibitor |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250186453A1 (https=) |
| EP (1) | EP4504197A4 (https=) |
| JP (1) | JP2025513802A (https=) |
| KR (1) | KR20250002214A (https=) |
| CN (1) | CN118973580A (https=) |
| AU (1) | AU2023250314A1 (https=) |
| CA (2) | CA3245730A1 (https=) |
| IL (1) | IL315648A (https=) |
| MX (1) | MX2024012446A (https=) |
| WO (1) | WO2023196218A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022271679A1 (en) * | 2021-06-21 | 2022-12-29 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558979B1 (en) * | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| PH12022551513A1 (en) * | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| AU2021263742A1 (en) * | 2020-04-27 | 2022-09-22 | Verastem, Inc. | Methods of treating abnormal cell growth |
| WO2022051565A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions |
| WO2022051568A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions |
| US12280055B2 (en) * | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3221608A1 (en) * | 2021-06-14 | 2022-12-22 | Kumquat Biosciences Inc. | Fused heteroaryl compounds useful as anticancer agents |
| WO2022271679A1 (en) * | 2021-06-21 | 2022-12-29 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
-
2023
- 2023-04-03 AU AU2023250314A patent/AU2023250314A1/en active Pending
- 2023-04-03 WO PCT/US2023/017254 patent/WO2023196218A2/en not_active Ceased
- 2023-04-03 KR KR1020247033661A patent/KR20250002214A/ko active Pending
- 2023-04-03 IL IL315648A patent/IL315648A/en unknown
- 2023-04-03 EP EP23785216.5A patent/EP4504197A4/en active Pending
- 2023-04-03 US US18/852,225 patent/US20250186453A1/en active Pending
- 2023-04-03 CA CA3245730A patent/CA3245730A1/en active Pending
- 2023-04-03 JP JP2024559468A patent/JP2025513802A/ja active Pending
- 2023-04-03 CN CN202380032771.6A patent/CN118973580A/zh active Pending
- 2023-04-03 CA CA3255758A patent/CA3255758A1/en active Pending
-
2024
- 2024-10-07 MX MX2024012446A patent/MX2024012446A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012446A (es) | 2024-11-08 |
| WO2023196218A3 (en) | 2023-11-16 |
| JP2025513802A (ja) | 2025-04-30 |
| CA3255758A1 (en) | 2023-10-12 |
| US20250186453A1 (en) | 2025-06-12 |
| WO2023196218A2 (en) | 2023-10-12 |
| AU2023250314A1 (en) | 2024-10-03 |
| CA3245730A1 (en) | 2023-10-12 |
| CN118973580A (zh) | 2024-11-15 |
| KR20250002214A (ko) | 2025-01-07 |
| EP4504197A4 (en) | 2026-03-18 |
| EP4504197A2 (en) | 2025-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL311834A (en) | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods | |
| IL315645A (en) | Combination therapies comprising a sos1 inhibitor and an egfr inhibitor | |
| JP2025000629A5 (https=) | ||
| FI3849537T3 (fi) | Yhdistelmäterapioita | |
| JP2025000632A5 (https=) | ||
| IL311863A (en) | Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods | |
| IL274601B1 (en) | Kras g12c inhibitors | |
| JP2025000630A5 (https=) | ||
| JP2024537140A5 (https=) | ||
| JP2022548791A5 (https=) | ||
| JP2024537139A5 (https=) | ||
| IL315648A (en) | Combination therapy of SOS1 inhibitor and MEK inhibitor | |
| CA2661649A1 (en) | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate | |
| RU2012127988A (ru) | Гиалуронидаза и способ ее применения | |
| JP2024537137A5 (https=) | ||
| CA2657636A1 (en) | Positively charged water soluble prodrugs of ibuprofen with very fast skin penetration rate | |
| JP2025512999A5 (https=) | ||
| AU2003301184A1 (en) | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS | |
| JP2025513802A5 (https=) | ||
| IL319808A (en) | Combined treatments | |
| ES2248131T3 (es) | Combinacion de loteprednol y agonistas de adrenoceptor beta2 y su utilizacion por inhalacion para el tratamiento del asma bronquial. | |
| CN107613970A (zh) | 短效苯基烷基胺钙通道阻滞剂的高水溶性盐及其应用 | |
| WO2023019095A2 (en) | Momelotinib combination therapy | |
| EP4665722A1 (en) | Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile | |
| CN101721480B (zh) | 治疗骨骼、关节及皮肤疾病的中药组合物及其制备方法 |